Tag: ASX:SHL

Sonic Healthcare is under Algo Engine buy conditions.

The Fund focuses on Australian and United States large cap securities and ETFs, to deliver superior risk adjusted investment returns.

Our unique point of difference is our proprietary algorithm-based investment models which are designed to quantify market momentum and remove much of the emotional human bias in the investment decision-making process.

Two classes of units in the Fund are offered

Class A Units – which provide investment exposure to ASX listed securities and exchange traded funds.

Class B Units – which provide investment exposure to United States listed securities and exchange traded funds.

For more information, please call 1300 614 002.

Sonic Healthcare 1H21 Revenue $4.4bn, up 33% on the same time last year. EBITDA increased to $1.02bn and further growth of 5 – 10% into FY22 underpins our buy recommendation.

The balance sheet remains under-geared and we expect to see the company actively seeking M&A or JV opportunities.

SHL trades on a forward yield of 3.8%

Sonic Healthcare is looking oversold and we believe buying support will build within the $32.50 – $33.50 price range.

Sonic Healthcare is finding buying support and we’re likely to see an improvement in the short-term indicators as the stock price stabilizes near the $33.50 level. 

Sonic Healthcare is under Algo Engine buy conditions and is up 20% since being added to our model in February 2020.

We anticipate further EPS upgrades when Sonic reports 1HFY21 earnings on 18 Feb.

High single-digit earnings growth supports the 3.6% forward dividend yield.

Sonic Healthcare is finding buying support and we’re likely to see an improvement in the short-term indicators as the stock price stabilizes near the $32.50 level. 

Sonic Healthcare is finding buying support and we’re likely to see an improvement in the short-term indicators as the stock price stabilizes near the $32.50 level. 

Sonic Healthcare is finding buying support and we’re likely to see an improvement in the short-term indicators as the stock price stabilizes near the $32.50 level.